64389-34-0

Basic information

• Product Name: Benzenamine, 2-(1,3-dioxolan-2-yl)-4-methoxy-
• CAS NO: 64389-34-0
• Molecular Formula: C10H13NO3
• Molecular Weight: 195.218
• Mol File: 64389-34-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzenamine, 2-(1,3-dioxolan-2-yl)-4-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 2-(1,3-dioxolan-2-yl)-4-methoxy-(64389-34-0)
• EPA Substance Registry System: Benzenamine, 2-(1,3-dioxolan-2-yl)-4-methoxy-(64389-34-0)

Safety Data

• Hazardous Substances Data: 64389-34-0(Hazardous Substances Data)

Upstream product

• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 20357-24-8 5-methoxy-2-nitro-benzaldehyde 
• 73428-02-1 5-methoxy-2-nitrobenzaldehyde ethylene acetal 

Downstream Products

• 1361129-27-2 C₂₅H₂₅N₅O₂ 
• 850424-09-8 ethyl (2-formyl-4-methoxyphenyl)carbamate 
• 850424-11-2 2-chloro-6-methoxyquinazoline 
• 850424-10-1 6-methoxyquinazolin-2-ol 
• 1374336-64-7 N-(4-isopropylphenyl)-6-methoxyquinazolin-2-amine 
• 1361129-30-7 2-(4-isopropylphenylamino)quinazolin-6-ol 
• 850424-16-7 C₁₈H₁₉N₃O 
• 850424-15-6 C₁₉H₂₁N₃O 
• 850424-08-7 ethyl (2-(1,3-dioxolan-2-yl)-4-methoxyphenyl)carbamate 
• 64439-81-2 dl-10-hydroxycamptothecin 

Relevant articles and documents

BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR

The present disclosure describes biaryl triazole compounds, as well as their compositions and methods of use. The compounds inhibit the activity of macrophage migration inhibitory factor and are useful for the treatment of diseases, e.g., inflammatory dis

Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors

Compounds belonging to several scaffolds-quinazolines, quinolines and quinoxalines-were designed and synthesized as Raf kinase inhibitors. Scaffolds were assessed for in vitro BrafV600E inhibition, and overall kinase selectivity. Pharmacokinetic parameters for one of the scaffolds were also determined.

2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase

New substituted quinazoline, quinoxaline, quinoline and isoquinoline compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.